Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study of JDQ443 and Ribociclib in Combination for Adult Patients with Advanced Solid Tumors with KRAS G12C Mutation

Fast replyRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying treatments for patients with advanced cancer that has a specific mutation called KRAS G12C. The study involves patients with different types of solid tumors, including those that are metastatic, meaning the cancer has spread to other parts of the body, or unresectable, meaning it cannot be removed with surgery. The main purpose of the study is to explore the safety and effectiveness of various treatment combinations.

The treatments being tested include a medication with the code name JDQ443, which is taken as a tablet. Other medications involved in the study are LEE011 (known as ribociclib), Mekinist (known as trametinib), and TMT212 (a form of trametinib dimethyl sulfoxide). Additionally, Cetuximab, which is given as an infusion into a vein, is also part of the study. Some patients may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatments.

The study is conducted in two phases. The first phase involves gradually increasing the dose of the medications to determine the safest and most effective dose. The second phase assesses how well the treatments work in controlling the cancer. Participants will take the medications as directed and attend regular check-ups to monitor their health and the cancer's response to the treatment. The study aims to find the best treatment combinations for future use in patients with this specific genetic mutation.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, you will be informed about the trial's purpose, procedures, and potential risks and benefits. You will be asked to provide informed consent, which means you agree to participate after understanding all the details.

  2. Step 2

    Initial assessment

    An initial assessment will be conducted to confirm your eligibility. This may include a review of your medical history, physical examination, and laboratory tests. You must have a specific gene mutation called KRAS G12C and meet other criteria to participate.

  3. Step 3

    Treatment phase

    During the treatment phase, you will receive the study medication. The main medication being tested is JDQ443, which is taken orally. You may also receive other medications in combination, such as LEE011, Mekinist, or Cetuximab, depending on your specific treatment plan.

    The dosage and frequency of the medications will be determined by the study team and may vary based on the phase of the trial and your response to the treatment.

  4. Step 4

    Regular monitoring

    Throughout the trial, you will have regular visits to monitor your health and the effects of the treatment. This includes physical exams, blood tests, and imaging studies to assess the tumor's response.

    You will be asked to report any side effects or changes in your health to the study team.

  5. Step 5

    Dose adjustment

    If necessary, the study team may adjust your medication dose based on your tolerance and any side effects experienced. This is to ensure your safety and the effectiveness of the treatment.

  6. Step 6

    End of treatment

    At the end of the treatment phase, a final assessment will be conducted to evaluate the overall response to the treatment. This may include additional tests and imaging studies.

    You will be informed about the results and any further steps or follow-up care needed.

Who can join the trial?

7 criteria

  • Patients must be adults with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors. This means the cancer has spread or cannot be removed by surgery and has a specific genetic change called KRAS G12C.
  • For the dose escalation part of the study, patients should have already received standard treatment or be unable to receive it.
  • For Phase II of the study, patients with advanced non-small cell lung cancer must have received a platinum-based chemotherapy and a type of treatment called an immune checkpoint inhibitor, unless they were not eligible for these treatments.
  • For Phase II of the study, patients with advanced colorectal cancer must have received specific chemotherapy treatments, unless they were not eligible for these treatments.
  • All patients must have an ECOG performance status of 0 or 1. This is a scale that measures how well patients can perform daily activities, with 0 being fully active and 1 being restricted in physically strenuous activity but able to carry out light work.
  • All patients must have a part of their disease that can be biopsied, meaning a small sample can be taken for testing, and they must be suitable for this procedure according to their doctor's guidelines.
  • Both male and female patients can participate.

Who cannot join the trial?

5 criteria

  • Patients who do not have a **KRAS G12C mutant solid tumor**. This means the specific type of cancer cell mutation must be present.
  • Patients whose cancer is not **advanced**. This refers to cancer that has spread to other parts of the body or cannot be removed by surgery.
  • Patients who are not adults. Only adult patients can participate.
  • Patients who are not able to understand or agree to the study requirements.
  • Patients who are part of a **vulnerable population**. This includes groups who may need special protection, like children or those unable to make decisions for themselves.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

JDQ443 is an experimental medication being tested in this clinical trial. It is designed to target a specific mutation in cancer cells known as KRAS G12C. This mutation is found in some advanced solid tumors, and the medication aims to block the activity of the mutated protein, potentially slowing down or stopping the growth of the cancer. The trial is exploring how safe and tolerable this medication is for patients, as well as its effectiveness in reducing tumor size or slowing tumor growth.

What is already known about the treatment

JDQ443 – JDQ443 is administered orally and is currently being studied in clinical trials for its potential use in treating adult patients with advanced solid tumors that have a specific genetic mutation known as KRAS G12C. This medication is still under investigation, and researchers are working to understand its safety, tolerability, and effectiveness in shrinking tumors. JDQ443 works by targeting and inhibiting the activity of the KRAS G12C protein, which plays a role in the growth and survival of cancer cells. It is classified as a targeted cancer therapy, aiming to specifically attack cancer cells with this mutation while sparing normal cells.

Investigated diseases

KRAS G12C Mutant Solid Tumors – KRAS G12C mutant solid tumors are a type of cancer characterized by a specific mutation in the KRAS gene, which is involved in cell signaling pathways that control cell growth and division. This mutation leads to uncontrolled cell proliferation, resulting in tumor formation. These tumors can occur in various organs, including the lungs, colon, and pancreas. As the disease progresses, the tumors may grow larger and spread to other parts of the body, becoming metastatic. The progression of these tumors can lead to symptoms such as pain, weight loss, and fatigue, depending on the location and size of the tumors. The disease is often diagnosed at an advanced stage when the tumors are either metastatic or cannot be surgically removed.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase ITrial ID2023-506716-41-00Protocol codeCJDQ443E12101Estimated enrolment350 patientsSponsorNovartis Pharma AG

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.